<DOC>
	<DOCNO>NCT02469116</DOCNO>
	<brief_summary>In study investigator use AUC 6 base creatinine clearance use Carboplatin dose formula use Gynecologic Oncology Group protocols . Given myelosuppression significant use docetaxel dose 75 mg/m*2 SCOTROC trial , prophylactic use pegylated G-CSF Phase II trial warrant . The expectation would patient able receive cycle timely fashion , less delay , thereby allow improve outcome decreased hospitalization due myelosuppression .</brief_summary>
	<brief_title>Carboplatin Plus Docetaxel With Day 2 Pegylated G-CSF ( Neulasta® ) Patients With Advanced Stage Ovarian Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Histologically confirm newly diagnose Stage III/IV epithelial ovarian primary peritoneal carcinoma time initial diagnosis Treatment must start within 8 week surgery Subjects may measurable per RECIST criterion evaluable disease response CA125 . Evaluable CA 125 level define elevate CA125 pre operatively either remain elevated postoperatively normalizes surgery No prior chemotherapy radiation therapy Age ≥ 18 Performance Status must ≤ 2 ( ECOG ) Peripheral neuropathy : must ≤ grade 1 Hematologic ( minimal value ) Absolute neutrophil count ≥ 1,500/mm3 Hemoglobin ≥ 8.0 g/dl Platelet count ≥ 100,000/mm3 Hepatic *Total Bilirubin ≤ ULN AST ALT Alkaline Phosphatase must within range allow eligibility . If alkaline phosphatase ≤ ULN AST ALT &gt; 5x ULN patient eligible If alkaline phosphatase &gt; 1x ≤2.5 x ULN AST ALT &gt; 1.5x ULN patient eligible If alkaline phosphatase &gt; 2.5x ≤5x ULN AST ALT &gt; 1x ULN patient eligible If alkaline phosphatase &gt; 5x ULN patient eligible Renal : Creatinine ( serum ) less equal 1.5 ULN , CTC grade 1 . Women childbearing potential must negative pregnancy test must willing consent use effective contraception treatment least 3 month thereafter . PT/PTT ≤ 1.5 x 's ULN Patients history severe hypersensitivity reaction Docetaxel drug formulate polysorbate 80 . Women pregnant breastfeeding . Patients sign infection recover effect recent surgery Patients performance status 3 4 Patients second malignancy within past 5 year nonmelanoma skin carcinoma . Patients receive prior myelosuppressive chemotherapy XRT .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>